All In Biotech

Drug Trial Radar · NCT02070978

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)

Last checked: Nov 20, 2026Latest source record: Mar 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

253

Actual

Start

Jul 29, 2014

Primary completion

Apr 5, 2016

Study completion Feb 9, 2018

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
First posted
Feb 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus erythematosus (SLE). Participants who completed the 24-week core study ADDRESS II core study (NCT01972568) and thus not met any of the discontinuation criteria were invited to enter this long-term extension (LTE) study NCT02070978.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • Atacicept 75 mgDrug

    Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.

  • Atacicept 150 mgDrug

    Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.

  • Atacicept 150 mgDrug

    Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Serious Adverse Event (SAE) During the Treatment PeriodTime frame: Baseline (LTE Day 1) up to maximum treatment duration of 143.7 weeks
  2. Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)Time frame: Baseline (Day 1 of Core study) up to maximum duration of 167.7 weeks

Locations

84 sites in 17 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group LLC

    Anniston, Alabama

  • University of Alabama at Birmingham - (UAB)

    Birmingham, Alabama

  • Wallace Rheumatic Study Center

    Beverly Hills, California

  • Southern California Permenent Medical Group

    Fontana, California

  • East Bay Rheumatology Medical Group, Inc.

    San Leandro, California

  • Clinical Research of West Florida - Corporate

    Clearwater, Florida

  • Clinical Research of West Florida, Inc.

    Tampa, Florida

  • McIlwain Medical Group, PA

    Tampa, Florida

  • AA MRC LLC Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Clayton Medical Associates, P.C.

    St Louis, Missouri

  • Rutgers New Jersey Medical School

    Newark, New Jersey

  • The Feinstein Institute for Medical Research

    Manhasset, New York

  • Hospital for Special Surgery

    New York, New York

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina

  • MetroHealth System

    Cleveland, Ohio

  • Arthritis & Rheumatology Center of Oklahoma

    Oklahoma City, Oklahoma

  • OMRF

    Oklahoma City, Oklahoma

  • Clinical Research Center of Reading LLC

    Wyomissing, Pennsylvania

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • Austin Regional Clinic, P.A.

    Austin, Texas

  • Little River Arthritis & Osteoporosis Clinic

    Waco, Texas

  • Organizacion Medica de Investigacion (OMI)

    Ciudad Autonoma Buenos Aires, Argentina

  • APRILLUS

    Ciudad Autonoma Buenos Aires, Argentina

  • Atencion Integral en Reumatologia (AIR)

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, Argentina

  • Cordis S.A.

    Salta, Argentina

  • Centro Polivalente de Asistencia e Inv. Clinica CER

    San Juan, Argentina

  • Instituto CAICI

    Rosario, Santa Fe Province, Argentina

  • Centro Medico Privado de Reumatologia

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Centro Integral de Reumatologia

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Investigaciones Clinicas Tucuman

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Centro de Pesquisas em Diabetes Ltda.

    Porto Alegre, Rio Grande do Sul, Brazil

  • MHAT "Eurohospital" - Plovdiv, OOD

    Plovdiv, Bulgaria

  • Medical Center "Teodora", EOOD

    Rousse, Bulgaria

  • MHAT - Ruse, AD

    Rousse, Bulgaria

  • UMHAT "Sv. Ivan Rilski", EAD

    Sofia, Bulgaria

  • DCC "Sveta Anna", EOOD

    Sofia, Bulgaria

  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD

    Stara Zagora, Bulgaria

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.